EP3960234B1 - Irradiation therapy device for self-treating parkinson's disease - Google Patents

Irradiation therapy device for self-treating parkinson's disease Download PDF

Info

Publication number
EP3960234B1
EP3960234B1 EP20193781.0A EP20193781A EP3960234B1 EP 3960234 B1 EP3960234 B1 EP 3960234B1 EP 20193781 A EP20193781 A EP 20193781A EP 3960234 B1 EP3960234 B1 EP 3960234B1
Authority
EP
European Patent Office
Prior art keywords
irradiation
led
bandwidth
light
head
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP20193781.0A
Other languages
German (de)
French (fr)
Other versions
EP3960234A1 (en
Inventor
Rudolf Haller
Jiajin HUANG
Hsi-Nan Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanomax
Original Assignee
Nanomax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanomax filed Critical Nanomax
Priority to EP20193781.0A priority Critical patent/EP3960234B1/en
Publication of EP3960234A1 publication Critical patent/EP3960234A1/en
Application granted granted Critical
Publication of EP3960234B1 publication Critical patent/EP3960234B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0618—Psychological treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/0622—Optical stimulation for exciting neural tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0635—Radiation therapy using light characterised by the body area to be irradiated
    • A61N2005/0643—Applicators, probes irradiating specific body areas in close proximity
    • A61N2005/0645—Applicators worn by the patient
    • A61N2005/0647—Applicators worn by the patient the applicator adapted to be worn on the head
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A61N2005/0652—Arrays of diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light

Definitions

  • Parkinson's disease is an asymmetric neurodegenerative disease affecting the dopaminergic neurons especially in the basal ganglia causing cardinal motor symptoms as bradykinesia, tremor, and rigidity, leading to a progressive loss of nerve cells in the brain especially at substantia nigra. Those affected suffer from speech disorders, mood swings, reduced mobility and the muscle tremor.
  • First line treatment for PD is generally by drug therapy using dopamine replacement medications. Once the right dose for each person is established the medication generally is controlling the symptoms of Parkinson's. Over time however; the effects of drugs often are no longer sufficient to manage the symptoms. Side effects can develop along with disease progression.
  • PD treatment traditionally has been to manage symptoms, not to modify the disease by slowing or stopping it or to create any neuro-protections. Patients diagnosed since 10 years with PD consume on average a dose of 700 mg till up over 1000 mg max. of dopamineregic drugs, with the danger of a severe side effect, known as "freezing", where the patient is suddenly in a paralysis, unable to move forward, which makes it desirable to keep the necessary medication as low as possible.
  • Parkinson's disease is known since more than 200 years, no cure is available, but several approaches of treatment are on market and under evaluation, where invasive and non-invasive methods are applied.
  • Invasive methods mainly are DBS (deep brain stimulation ) and stem cell therapies, non-invasive therapies mostly use sound or magnetic and electric waves to stimulate brain cells.
  • non-invasive therapies are electro-magnetic-based Transcranial Magnetic Stimulation (TMS), in which the nerve cells in the brain are activated or even inhibited via magnetic fields, or Transcranial Puls Stimulation ( TPS ) applying light pulses on a limited skull area to stimulate nerve cells, or Focused Ultra Sonic (FUS) therapy, mechanically interrupting nerve channels responsible for uncontrolled hand tremor by overheating a focused brain area to destroy specific nerve cells.
  • TMS Transcranial Magnetic Stimulation
  • TPS Transcranial Puls Stimulation
  • FUS Focused Ultra Sonic
  • a specific non-invasive therapy for wound-healing, skin-treatment, pain relieve, hair-grow is using semiconductor emitters like Light Emitting Diodes (LED) or Vertical Cavity Surface Emitting Laser (VCSEL), mostly with visible and near infra-red light spectrum, and named as Low-Light-Level-Theraypy (LLLT), Photo-Bio-Modulation Therapy (PBMT ) and other termini, covering all the same approach: influencing cell beneficial behavior by light.
  • LED Light Emitting Diodes
  • VCSEL Vertical Cavity Surface Emitting Laser
  • LLLT Low-Light-Level-Theraypy
  • PBMT Photo-Bio-Modulation Therapy
  • ATP Adenosine Tri Phosphate
  • ROS Reactive Oxygen Species
  • NO Nitric Oxide
  • ICa2+ Inter cellular Calcium
  • Boosting additional NO generation light energy of a bandwidth of 405 nm ⁇ 20 nm is known and analyzed in several studies.
  • document US2011/0092863 A1 provides a helmet-shaped device configured to irradiate patient's scalp using light in four different wavelength ranges.
  • the technical problem, solved by underlying invention is to apply irradiation on human head to penetrate hair, scalp, skull and brain tissue in a sufficient depth to ignite biochemical processes, well described in plural studies in vitro as in vivo.
  • irradiation placement as well as irradiation placement modification, irradiation-wavelength, together with environmental conditions hygienically factors, and wear-ability of the device is the core of disclosed invention.
  • the invention is comprising a portable-, wearable helmet-shaped head cover Fig. 16 , containing an outer shell base-ABS part 96 , a removable outer-shell top-ABS part 95 , with a combined Light Emitting Diode ( LED ) array Fig. 3 and an integrated LASER module Fig. 6 , as illustrated in Fig.
  • LED Light Emitting Diode
  • a flexible printed circuit board (PCB ) 90 shaped according a spherical cutting pattern to achieve sufficient ventilation slots 92 , with an onboard Master Control Unit ( MCU ) 91 placed under the removable outer shell top ABS part, as well as sketched in Fig 3 includes 1440 Light Emitting Diodes ( LED ) as non-coherent light sources in bandwidth of 660 nm ⁇ 20 nm 40, 850 nm ⁇ 20 nm 41, 1550 nm ⁇ 20 nm 42 and 405 nm ⁇ 20 nm 45 shown in Fig.
  • LED Light Emitting Diodes
  • the device is intended to support sub-cellular neuronal bio-chemical processes leading in reduction of stiffness, movement disorders, and promoting relaxation of muscles, whereas the VCSEL laser adapter at ear delivers normal radiation therapy through the skull, but on nose is intended to breach the blood-brain-barrier( BBB ) allowing drugs delivery via the nasal cavity inside the brain, known as Intranasal Nose-to Brain Delivery.
  • the full size helmet style shown in Fig. 21 , is covering forehead, ears, and back head till to neck, with a full irradiation influence on total skull 103 emitted bv tight arranged light sources 102.
  • Fig. 1 shows the electronic schema of the underlying patent comprising a 12V/20 Ah powerbank 1 , an 32 bit Advanced RISC Machine ( ARM ) Micro Controller Unit ( MCU ) 2 , Touch buttons for power- 3 and mode- 4 -input, an Unified Serial Bus ( USB ) 5 for software update, laser module output for laser modules 6 ,7 , the software controlled frequency rhythm 8, power level 9, by Pulse Wide Modulation .10 , a Temperature security shutdown regulator 11, a Timer module 12, a Wi-Fi router 13, communicating through Wi-Fi 14 , with controlling devices as PC 15, or Notebook 16, or Smartphone 17 , and Tablet 18 , operating on Windows, iOS, Linux, and Android software.
  • ARM Advanced RISC Machine
  • MCU Micro Controller Unit
  • Fig. 2 shows the Graphical User Interface (GU ) used to control parameters of the invention like ON / OFF switch 19 , full flashing mode, blinking all 1440 pieces LEDs 20 , a flashing mode with diagonal- 21, spiral- 22 , rotation 23, strobe- 24, wave- 25 irradiation-pattern and rhythm, as well a preset frequency rhythm as fast 26 or slow 27 .
  • GUI Graphical User Interface
  • Fig. 3 is a drawing of the flexible PCB inner side 36 , which is faced to skull, ( flat, unfolded ) with 360 pieces of SMD mounted LED sockets comprising quadruple light sources of totaling 1440 individual light sources.
  • Fig. 4 is a magnified presentation of the flexible PCB inner side ( flat, unfolded ) 39 , showing LED socket 38 mounted as LED array on a single segment..
  • Fig. 5 is a top view of the four light sources 40 , 41 , 42, and 45, with a side view 43, and bottom view 44 of the LED socket, together with their electric symbolic chart 46 . Also demonstrating irradiation beams emitted by the quadruple light sources, mounted on a single LED socket 47 , illuminating the skull surface 52 with symbolized irradiation beam of 660 nm ⁇ 20 nm 48 , 850 nm ⁇ 20 nm 49 ,1550 nm ⁇ 20 nm 50 ,and 450 nm ⁇ 20 nm 51 .
  • Fig. 6 shows the two ear/ nose laser modules 55, comprising the laser itself 53 with Infra-Red wavelength of 850 nm ⁇ 1 nm, together with green indication LED 54 , and the electrical symbol chart of laser 1 57, laser function-indicator 1 58, laser 2 59 and laser function-indicator 2 60 , allowing simultaneously the usage of head-, and ear- or nose- irradiation .
  • Fig. 7 is showing the outer-, or top-side-flexible PCB, facing away from head, containing 5 pieces of frontal segments 61, 7 pieces of side and back segments 62, and 1 center-top segment 63 .
  • Fig. 8 shows mounted MCU 64 and driver Integrated Circuits ( IC ) 65 of center-top-segment..
  • Fig. 9 shows a symbolic electrical chart, illustrating " irradiation segment 1" 66, “ irradiation segment 2 " 67 , “irradiation segment 12 “ 68 , and “ irradiation segment 13 “, as well as laser 1 70, indicator 1 71, laser 2 72, indicator 2 73 .
  • Fig. 10 illustrates the incremental process during power-rise 74 , the overlaying 40 Hz pulse frequency 75 , and the 0.25 Hz pulsing frequency of laser modules 76.
  • Fig. 11 shows characteristic wavelength data of LED 660 nm ⁇ 20 nm 77, of LED 850 nm ⁇ 20 nm 78, of LED 1550 nm ⁇ 20 nm 79 and of LED 405 nm ⁇ 20 nm 80 .
  • Fig. 12 shows characteristic wavelength data of laser 850 nm ⁇ 1 nm 81, the illumination angle thereof 82 , and the typical illumination angle of implemented LEDs. 83 .
  • Fig. 13 depict the different illumination modes controlled by MCU,” rotate “84 , incrementing circular 4 segments in cycle, “ spiral “ 85 , incrementing circular segments in cycle,” wave “ 86 , incrementing alternating circular 4 segments in cycle,” cross “ 87 , incrementing diagonal segments in cycle,” strobe “ 88 , incrementing randomized segments in cycle,” full” 89 , pulsing all segments in cycle,
  • Fig. 14 shows the bent flexible PCB covering full forehead, till back to neck, including ears 90 , and top mounted MCU 91 , constructed to allow ventilation channels 92 for cooling.
  • Fig. 15 shows the combined wearable helmet cover without the between inner- 94 and outer shield 93, mounted flexible PCB.
  • Fig. 16 shows the upper- 95 , and lower-part 96 , of the outer shell of the helmet, which covers the flexible PCB on top.
  • Fig. 17 shows the left side of the device with touch button for flash mode selection 98 and plug for laser module 97.
  • Fig. 18 is the back view with the USB plug 99 used for software upload.
  • Fig. 19 is the drawing of the inner shell 100 , protecting the flexible PCB, manufactured in clear optical PMMA to reduce optical losses to a minimum.
  • Fig. 20 shows, in cross section view, the tight assembly of LED light sources 101 covering the head from forehead till back to neck, including ears.
  • Fig. 21 symbolizes, in cross section view, the deep penetration of light energy till into the brain tissue 103 , emitted by light sources 102 .
  • Fig. 22 demonstrates four different light beams 104 , with different wavelength, penetrating between hairs 105 , through scalp 106, skull 107 and brain tissue 108 in different depths, where higher wavelength assures deeper penetration, but blue light activates surface of scalp only.
  • Fig. 23 shows the bio-chemical reaction caused by the light irradiation in different wavelengths, resulting for example in a positive stimulation of Adenosine Tri Phosphate ( ATP ) production in phase V 110 of the Electron Transport Chain ( ETC ) 109 on the inner membrane of mitochondria ( 111 ), but also stimulating for example Reactive Oxygen Species ( ROS ) or Nitric Oxide ( NO ).
  • ROS Reactive Oxygen Species
  • NO Nitric Oxide
  • Fig. 24 is a topographic chart of the brain activities, where lighter color areas 112 correspondent to lower, and darker colored areas 113 to higher brain activities, measured at 19 electrodes, placed according the electrode schemes 114 .
  • Fig. 25 is showing the result of an Electroencephalogram ( EEG ) analysis, which was recorded before, and after 20 min irradiation, plotting brainwaves in Alpha bandwidth ( 9 - 14 Hz) 118, Beta bandwidth ( 15 - 30 Hz ) 120 , Delta Bandwidth ( 1 - 3 Hz ) 117 , and Theta bandwidth ( 4- 8 Hz ) 119 charted before " pre " 115 and after " post” 116 irradiation, illustrating a significant increase of Alpha activities, signaling calm stable relaxation without of signs of anxiousness, an increase of Beta activities, especially on forehead demonstrating an awake activity, and slight increase in Theta activity, prescribed as a status of "deep relaxation ", demonstrating positive influence of underlying invention on brain activities after irradiation.
  • EEG Electroencephalogram
  • UDRS Unified Parkinson's Disease Rating Scale
  • ADL Schwab and England Activities of Daily Living Scale
  • PDQ-39 Parkinson's Disease Questionnaire
  • Fig. 26 is comparing abilities and impairments of 7 patients and 1 control person.
  • the invention is comprising a portable-, wearable helmet-shaped head cover, as shown in Fig. 16 , containing an outer shell base-ABS part 96 , a removable outer-shell top-ABS part 95 , with a combined Light Emitting Diode ( LED ) array Fig. 3 emitting incoherent light at a wavelength of between 405 nm and 1550 nm, and an integrated LASER module Fig. 6 emitting coherent infra-red light at a wavelength of 850 nm, as illustrated in Fig.
  • LED Light Emitting Diode
  • a flexible printed circuit board ( PCB ) 90 shaped according a spherical cutting pattern to achieve sufficient ventilation slots 92 , with an onboard Master Control Unit ( MCU ) 91 placed under the removable outer shell top ABS part, as well as sketched in Fig 3 includes 1440 Light Emitting Diodes ( LED ) as non-coherent light sources in bandwidth of 660 nm ⁇ 20 nm 40 , 850 nm ⁇ 20 nm 41, 1550 nm ⁇ 20 nm 42 and 405 nm ⁇ 20 nm 45 shown in Fig.
  • LED Light Emitting Diodes
  • the device is intended to support sub-and intra-cellular neuronal bio-chemical processes, leading in reduction of stiffness, reducing movement disorders, and promoting relaxation of muscles, whereas the VCSEL laser adapter at ear delivers normal radiation therapy through the skull, but used on nose, it is intended to breach the blood-brain-barrier( BBB ), allowing drugs delivery via the nasal cavity inside the brain, known as Intranasal Nose-to Brain Delivery.
  • the full size helmet style shown in Fig. 21 , is covering forehead, ears, and back head till to neck, with a full irradiation influence on total skull 103 emitted by tight arranged light sources 102.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Disabilities (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Social Psychology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Radiation-Therapy Devices (AREA)

Description

    Background
  • Parkinson's disease (PD) is an asymmetric neurodegenerative disease affecting the dopaminergic neurons especially in the basal ganglia causing cardinal motor symptoms as bradykinesia, tremor, and rigidity, leading to a progressive loss of nerve cells in the brain especially at substantia nigra. Those affected suffer from speech disorders, mood swings, reduced mobility and the muscle tremor.
  • First line treatment for PD is generally by drug therapy using dopamine replacement medications. Once the right dose for each person is established the medication generally is controlling the symptoms of Parkinson's. Over time however; the effects of drugs often are no longer sufficient to manage the symptoms. Side effects can develop along with disease progression. PD treatment traditionally has been to manage symptoms, not to modify the disease by slowing or stopping it or to create any neuro-protections. Patients diagnosed since 10 years with PD consume on average a dose of 700 mg till up over 1000 mg max. of dopamineregic drugs, with the danger of a severe side effect, known as "freezing", where the patient is suddenly in a paralysis, unable to move forward, which makes it desirable to keep the necessary medication as low as possible.
  • Although Parkinson's disease is known since more than 200 years, no cure is available, but several approaches of treatment are on market and under evaluation, where invasive and non-invasive methods are applied.
  • Invasive methods mainly are DBS (deep brain stimulation ) and stem cell therapies, non-invasive therapies mostly use sound or magnetic and electric waves to stimulate brain cells. Examples of common non-invasive therapies are electro-magnetic-based Transcranial Magnetic Stimulation (TMS), in which the nerve cells in the brain are activated or even inhibited via magnetic fields, or Transcranial Puls Stimulation ( TPS ) applying light pulses on a limited skull area to stimulate nerve cells, or Focused Ultra Sonic (FUS) therapy, mechanically interrupting nerve channels responsible for uncontrolled hand tremor by overheating a focused brain area to destroy specific nerve cells.
  • A specific non-invasive therapy for wound-healing, skin-treatment, pain relieve, hair-grow is using semiconductor emitters like Light Emitting Diodes (LED) or Vertical Cavity Surface Emitting Laser (VCSEL), mostly with visible and near infra-red light spectrum, and named as Low-Light-Level-Theraypy (LLLT), Photo-Bio-Modulation Therapy ( PBMT ) and other termini, covering all the same approach: influencing cell beneficial behavior by light.
  • The influence of red or near infrared- as well as blue light on mammalian cells is observed as supporting element for the production of Adenosine Tri Phosphate (ATP), which is commonly referred to as the "power house" or "energy currency" of the cell, as it provides energy, and breakdown of ATP through hydrolysis, serves a broad range of functions in the cell, including signaling and DNA/RNA synthesis, where the influence of absorbance of photogenic energy on the signaling pathway of exosomes is under evaluation, further also leading to a regulation of Reactive Oxygen Species ( ROS ), Nitric Oxide ( NO ) and Inter cellular Calcium ( ICa2+ ).
  • Boosting additional NO generation light energy of a bandwidth of 405 nm ±20 nm is known and analyzed in several studies.
  • Light energy is absorbed by chromophores inside the mitochondria, supporting the Cytochrome C Oxidase ( CCO ) at complex V of the Electron Transport Chain ( ETC ) of the mitochondrion inner membrane converting Adenosine Duo Phosphate ( ADP ) to ATP at the ATP synthase , but not being exclusively primary receptor for near infrared light.
  • PRIOR ART STUDIES and PUBLICATIONS
  • Available animal or human studies are describing beneficial outcome of different irradiation-therapies with light-sources in wavelength range from red- infra-red- and blue light bandwidth, without disclosure of a useful portable device to treat Parkinson patients.
    • C.L. Hamilton, J Mitrofanis e.a. Australia " light -bucket"
    • C. Hamilton, D.Hamilton, e.a.
    • M.R. Hamblin , Fahrzad Salehpoure.a GER, USA "PD animal study
    • S. Rutten, Vrije University, NETHERLAND
  • Furthermore, document US2011/0092863 A1 provides a helmet-shaped device configured to irradiate patient's scalp using light in four different wavelength ranges.
  • PRIOR ART DEVICES
  • On the market are available -Photo-Bio-Modulation-devices, for home-use with portable conception, or stand-alone-design, are based on semi-spherical helmet shaped devices containing single mounted light sources ( LEDs or laser in numbers of at about 250 pieces max.), mostly claiming beneficial hair growth effects, as well as " supporting brain health ", or hand-held therapy-devices with only few irradiation LEDs or lasers, which are placed by a therapist on the head of patients. Even therapy devices constructed by hobbyists, like a bucket containing simple red light LED-stripes are known to be used by patients, and described as " light bucket ".
  • A FDA approved Clinical Trial ( NCT02175472 )Photo Pharmics Spectramax USA; is using a table-top lamp emitting green/blue light, with outcomes, even questioned by the researcher. Although several animal and human studies showed beneficiary effects on brain injuries as well on Parkinson's disease, current devices are without conception to penetrate skull and brain tissue in a sufficient stimulating way with different power-settings, radiant energy, tight placements of light-sources, and optimized head coverage, together with sequential flashing modes, which is base of underlying invention.
  • Field of invention
  • Medical treatment of Parkinson's Disease ( PD ) by trans-cranial irradiation.
  • The invention and its most advantageous embodiments are defined in the appended set of claims.
  • The technical problem, solved by underlying invention is to apply irradiation on human head to penetrate hair, scalp, skull and brain tissue in a sufficient depth to ignite biochemical processes, well described in plural studies in vitro as in vivo. Considering optimal power, power-modification, irradiation placement as well as irradiation placement modification, irradiation-wavelength, together with environmental conditions hygienically factors, and wear-ability of the device is the core of disclosed invention.
  • The invention is comprising a portable-, wearable helmet-shaped head cover Fig. 16, containing an outer shell base-ABS part 96 , a removable outer-shell top-ABS part 95 , with a combined Light Emitting Diode ( LED ) array Fig. 3 and an integrated LASER module Fig. 6 , as illustrated in Fig. 14 a flexible printed circuit board (PCB ) 90 , shaped according a spherical cutting pattern to achieve sufficient ventilation slots 92 , with an onboard Master Control Unit ( MCU ) 91 placed under the removable outer shell top ABS part, as well as sketched in Fig 3 includes 1440 Light Emitting Diodes ( LED ) as non-coherent light sources in bandwidth of 660 nm ±20 nm 40, 850 nm ±20 nm 41, 1550 nm ±20 nm 42 and 405 nm ±20 nm 45 shown in Fig. 5, with drawing of side-view 43 and bottom-view 44 together with electrical chart of the quadruple light source 46 , mounted as single chip on a 5050 LED socket 47 thereafter soldered on a PCB as surface mounted devices (SMD) as shown in Fig. 4. An optical grade transparent Polymethyl Methacrylate ( PMMA ) inner shell, Fig. 19 , protecting the emitting light sources, assuring irradiation without loss and hygienic clean ability for multiple usage.
  • The device is intended to support sub-cellular neuronal bio-chemical processes leading in reduction of stiffness, movement disorders, and promoting relaxation of muscles, whereas the VCSEL laser adapter at ear delivers normal radiation therapy through the skull, but on nose is intended to breach the blood-brain-barrier( BBB ) allowing drugs delivery via the nasal cavity inside the brain, known as Intranasal Nose-to Brain Delivery. The full size helmet style, shown in Fig. 21, is covering forehead, ears, and back head till to neck, with a full irradiation influence on total skull 103 emitted bv tight arranged light sources 102.
  • Fig. 1 shows the electronic schema of the underlying patent comprising a 12V/20 Ah powerbank 1 , an 32 bit Advanced RISC Machine ( ARM ) Micro Controller Unit ( MCU ) 2 , Touch buttons for power- 3 and mode- 4 -input, an Unified Serial Bus ( USB ) 5 for software update, laser module output for laser modules 6 ,7 , the software controlled frequency rhythm 8, power level 9, by Pulse Wide Modulation .10 , a Temperature security shutdown regulator 11, a Timer module 12, a Wi-Fi router 13, communicating through Wi-Fi 14 , with controlling devices as PC 15, or Notebook 16, or Smartphone 17 , and Tablet 18 , operating on Windows, iOS, Linux, and Android software.
  • Fig. 2 shows the Graphical User Interface ( GUI ) used to control parameters of the invention like ON / OFF switch 19 , full flashing mode, blinking all 1440 pieces LEDs 20 , a flashing mode with diagonal- 21, spiral- 22 , rotation 23, strobe- 24, wave- 25 irradiation-pattern and rhythm, as well a preset frequency rhythm as fast 26 or slow 27 . With the slider "power" 31 irradiation power is adjusted, with slider " delay" 32 , delay time between increment steps of power is selected, with slider " time " 33 therapy time is chosen. Electrical values are displayed on scales 28 , inside helmet temperature is indicated at scale 29 , real time irradiation energy shown on scale 30 , transmission channel of actual controlled device ( in simultaneous multi-device / multi-channel operation mode ) is selected by drop-down menu 34 , and data recording is activated by switch 35.
  • Fig. 3 is a drawing of the flexible PCB inner side 36 , which is faced to skull, ( flat, unfolded ) with 360 pieces of SMD mounted LED sockets comprising quadruple light sources of totaling 1440 individual light sources.
  • Fig. 4 is a magnified presentation of the flexible PCB inner side ( flat, unfolded ) 39 , showing LED socket 38 mounted as LED array on a single segment..
  • Fig. 5 is a top view of the four light sources 40 , 41 , 42, and 45, with a side view 43, and bottom view 44 of the LED socket, together with their electric symbolic chart 46 . Also demonstrating irradiation beams emitted by the quadruple light sources, mounted on a single LED socket 47 , illuminating the skull surface 52 with symbolized irradiation beam of 660 nm ±20 nm 48 , 850 nm ±20 nm 49 ,1550 nm ±20 nm 50 ,and 450 nm ±20 nm 51 .
  • Fig. 6 shows the two ear/ nose laser modules 55, comprising the laser itself 53 with Infra-Red wavelength of 850 nm ±1 nm, together with green indication LED 54 , and the electrical symbol chart of laser 1 57, laser function-indicator 1 58, laser 2 59 and laser function-indicator 2 60 , allowing simultaneously the usage of head-, and ear- or nose- irradiation .
  • Fig. 7 is showing the outer-, or top-side-flexible PCB, facing away from head, containing 5 pieces of frontal segments 61, 7 pieces of side and back segments 62, and 1 center-top segment 63 .
  • Fig. 8 shows mounted MCU 64 and driver Integrated Circuits ( IC ) 65 of center-top-segment..
  • Fig. 9 shows a symbolic electrical chart, illustrating " irradiation segment 1" 66, " irradiation segment 2 " 67 , "irradiation segment 12 " 68 , and " irradiation segment 13 ", as well as laser 1 70, indicator 1 71, laser 2 72, indicator 2 73 .
  • Fig. 10 illustrates the incremental process during power-rise 74 , the overlaying 40 Hz pulse frequency 75 , and the 0.25 Hz pulsing frequency of laser modules 76.
  • Fig. 11 shows characteristic wavelength data of LED 660 nm ±20 nm 77, of LED 850 nm ±20 nm 78, of LED 1550 nm ±20 nm 79 and of LED 405 nm ±20 nm 80 .
  • Fig. 12 shows characteristic wavelength data of laser 850 nm ±1 nm 81, the illumination angle thereof 82 , and the typical illumination angle of implemented LEDs. 83 .
  • Fig. 13 depict the different illumination modes controlled by MCU," rotate "84 , incrementing circular 4 segments in cycle, " spiral " 85 , incrementing circular segments in cycle," wave " 86 , incrementing alternating circular 4 segments in cycle," cross " 87 , incrementing diagonal segments in cycle," strobe " 88 , incrementing randomized segments in cycle," full" 89 , pulsing all segments in cycle,
  • Fig. 14 shows the bent flexible PCB covering full forehead, till back to neck, including ears 90 , and top mounted MCU 91 , constructed to allow ventilation channels 92 for cooling.
  • Fig. 15 shows the combined wearable helmet cover without the between inner- 94 and outer shield 93, mounted flexible PCB.
  • Fig. 16 shows the upper- 95 , and lower-part 96 , of the outer shell of the helmet, which covers the flexible PCB on top.
  • Fig. 17 shows the left side of the device with touch button for flash mode selection 98 and plug for laser module 97.
  • Fig. 18 is the back view with the USB plug 99 used for software upload.
  • Fig. 19 is the drawing of the inner shell 100 , protecting the flexible PCB, manufactured in clear optical PMMA to reduce optical losses to a minimum.
  • Fig. 20 shows, in cross section view, the tight assembly of LED light sources 101 covering the head from forehead till back to neck, including ears.
  • Fig. 21 symbolizes, in cross section view, the deep penetration of light energy till into the brain tissue 103 , emitted by light sources 102 .
  • Fig. 22 demonstrates four different light beams 104 , with different wavelength, penetrating between hairs 105 , through scalp 106, skull 107 and brain tissue 108 in different depths, where higher wavelength assures deeper penetration, but blue light activates surface of scalp only. To achieve full penetration in different brain areas 4 different wavelength chips, namely 660 nm ±20 nm, 850 nm ±20 nm, 1550 nm ±20 nm and 405 nm ±20 nm are integrated on a single LED socket, delivering high intensity therapeutic 40 Hz pulsed photon energy, with a maximum irradiation flux intensity of 64 mW/cm2, 154 J/cm2 ( Root Mean Square (RMS)), on a full treatment surface of 188 cm2 .
  • Fig. 23 shows the bio-chemical reaction caused by the light irradiation in different wavelengths, resulting for example in a positive stimulation of Adenosine Tri Phosphate ( ATP ) production in phase V 110 of the Electron Transport Chain ( ETC ) 109 on the inner membrane of mitochondria ( 111 ), but also stimulating for example Reactive Oxygen Species ( ROS ) or Nitric Oxide ( NO ).
  • Fig. 24 is a topographic chart of the brain activities, where lighter color areas 112 correspondent to lower, and darker colored areas 113 to higher brain activities, measured at 19 electrodes, placed according the electrode schemes 114 .
  • Fig. 25 is showing the result of an Electroencephalogram ( EEG ) analysis, which was recorded before, and after 20 min irradiation, plotting brainwaves in Alpha bandwidth ( 9 - 14 Hz) 118, Beta bandwidth ( 15 - 30 Hz ) 120 , Delta Bandwidth ( 1 - 3 Hz ) 117 , and Theta bandwidth ( 4- 8 Hz ) 119 charted before " pre " 115 and after " post" 116 irradiation, illustrating a significant increase of Alpha activities, signaling calm stable relaxation without of signs of anxiousness, an increase of Beta activities, especially on forehead demonstrating an awake activity, and slight increase in Theta activity, prescribed as a status of "deep relaxation ", demonstrating positive influence of underlying invention on brain activities after irradiation.
    • Fig. 1 is a schematic overview of electronic components of an irradiation device related to the embodiment.
    • Fig. 2 depicts a screenshot of the Graphical User Interface ( GUI ) of the device's remote-controller interface.
    • Fig. 3 is a top view of the flexible PCB, inner side ( unshaped, in flat position ), showing the placement of light sources of the radiation device.
    • Fig. 4 is a magnified image of arranged Light Emitting Diodes ( LEDs).
    • Fig. 5 is a drawing with top-, side- and bottom view of a single light source module, and electrical chart thereof, additional sketch, symbolizing the overlapping irradiation coverage of scalp.
    • Fig. 6 is a sketch depicting two ear / nose adapter laser modules, as also their electrical chart.
    • Fig. 7 is showing the flexible PCB, complete upper side ( unshaped, in flat position ), with electronic control units and drivers mounted on top.
    • Fig. 8 is showing the flexible PCB, center segment, upper side ( unshaped, in flat position ), with MCU and drivers mounted on top.
    • Fig. 9 symbolizes the independent controlled 13 irradiation segments, as well as the ear/laser-module.
    • Fig. 10 illustrates electrical signal properties demonstrating power increase and pulsing.
    • Fig. 11 are irradiation characteristics of implemented LEDs .
    • Fig. 12 are characteristics of ear / nose laser module light source, and LED irradiation angle data.
    • Fig. 13 shows various flashing modes of the irradiation device.
    • Fig. 14 illustrates the bending of the flexible PCB segments to cover head.
    • Fig. 15.. is a 3D view of inner and outer helmet parts.
    • Fig. 16 is the front view of outer helmet parts ( with detached top part).
    • Fig. 17 is the side view of outer helmet parts showing arrangement of touch-button and laser plug ( with detached top part ).
    • Fig. 18 is the back view of outer helmet parts showing USB plug ( with detached top part ).
    • Fig. 19 is a 3 D-view of the inner optical transparent PMMA helmet part.
    • Fig. 20 shows a cross section and a 3D-view of the helmet device placed on a head.
    • Fig. 21 is a cross section of the irradiation helmet illustrating the full coverage of head, and placement of irradiation sources, as there penetration through skull.
    • Fig. 22 is a cross section of head, with parts of brain symbolizing photogenic penetration through hair, scalp, skull inside the brain.
    • Fig. 23 is a drawing of the inner membrane of mitochondria, focused on the electric transport chain ( ETC ) .
    • Fig. 24 shows pre and post irradiation results of Electroencephalogram ( EEG ) separated by different brainwaves as a topographical EEG scalp map.
    • .Fig. 25 shows pre and post irradiation results of Electroencephalogram ( EEG ) separated by different brainwaves as single electrode charts.
    • Fig 26. is a summary table of different assessments comparing the abilities and impairments of 7 patients and one control person.
    Method and outcome of study
  • Over a period of more than 2 years (November 2018 -June 2020) several systems of red /infra-red and blue light wavelength combinations were explored and tested on 7 patients ( 5 male, 2 female ), and 1 control person ( male ), ending up in an optimized quadruple-wavelength version of 660 nm 850 nm 1550 nm and 405 nm of irradiation LEDs, and therapy treatment time of 40 minutes twice a day
    Safety was assessed on the basis of adverse events, regularly observation of behavior, cognition , mobility, dyskinesia, falls, adverse changes in mood, and impulsivity. Treatment Emergent Adverse Events ( TEAEs) were defined as adverse events, starting on or after the date of the first use of radiation device.
  • Derived from Unified Parkinson's Disease Rating Scale (UDPRS), Hoehn and Yahr Scale, Schwab and England Activities of Daily Living Scale (ADL), and Parkinson's Disease Questionnaire (PDQ-39) tests and observations were expanded with outdoor activities to get a broader view of patients impairments, abilities and disabilities.
  • Fig. 26 is comparing abilities and impairments of 7 patients and 1 control person.
  • As in this situation a randomized double-blinded clinical study is not feasible, the study is not fully based on statistical data, but subjective observation, discussions and interviews by the examiner, not all data have quantitative data sets, but major findings and observations at the group attending the radiation therapy, are :
    • 1.) no progression of Parkinson's related disabilities.
    • 2.) reduction of medication intake of more than 50%.
    • 3.) stable movement abilities with minor tendencies to improvement of abilities.
    • 4.) improved freshness, spirit and motivation
    • 5.) radiation therapy is good tolerable, without treatment emergent adverse events. Whereas the group of patients treated with conventional dopaminergic medication was found to have:
    • 6) dramatic ( within a period of one year) progressive degeneration of movement abilities, as other worsening factor, till to hospitalization and depending on walker rollator. Further:
    • 7) no TEAEs at control group, but improved freshness and agility.
    Summary
  • The invention is comprising a portable-, wearable helmet-shaped head cover, as shown in Fig. 16 , containing an outer shell base-ABS part 96 , a removable outer-shell top-ABS part 95 , with a combined Light Emitting Diode ( LED ) array Fig. 3 emitting incoherent light at a wavelength of between 405 nm and 1550 nm, and an integrated LASER module Fig. 6 emitting coherent infra-red light at a wavelength of 850 nm, as illustrated in Fig. 14 a flexible printed circuit board ( PCB ) 90 , shaped according a spherical cutting pattern to achieve sufficient ventilation slots 92 , with an onboard Master Control Unit ( MCU ) 91 placed under the removable outer shell top ABS part, as well as sketched in Fig 3 includes 1440 Light Emitting Diodes ( LED ) as non-coherent light sources in bandwidth of 660 nm ±20 nm 40 , 850 nm ±20 nm 41, 1550 nm ±20 nm 42 and 405 nm ±20 nm 45 shown in Fig. 5, with drawing of side-view 43 and bottom-view 44 together with electrical chart of the quadruple light source 46 , mounted as single chip on a 5050 LED socket 47 thereafter soldered on a PCB as surface mounted devices (SMD) as shown in Fig. 4.
  • An optical grade transparent Polymethyl Methacrylate ( PMMA ) inner shell, Fig. 19 , protecting the emitting light sources, assuring irradiation without loss and hygienic clean ability for multiple usage.
  • The device is intended to support sub-and intra-cellular neuronal bio-chemical processes, leading in reduction of stiffness, reducing movement disorders, and promoting relaxation of muscles, whereas the VCSEL laser adapter at ear delivers normal radiation therapy through the skull, but used on nose, it is intended to breach the blood-brain-barrier( BBB ), allowing drugs delivery via the nasal cavity inside the brain, known as Intranasal Nose-to Brain Delivery. The full size helmet style, shown in Fig. 21, is covering forehead, ears, and back head till to neck, with a full irradiation influence on total skull 103 emitted by tight arranged light sources 102.

Claims (11)

  1. A portable helmet-shaped device configured to cover patient's head, the device comprising
    a PCB (39) and an array including 1440 non-coherent light sources grouped as quadruple light sources (46),
    wherein each quadruple light source (46) has an arrangement of four LEDs comprising
    a first LED (40, D1) configured to emit light in a bandwidth of 660 nm ±20 nm,
    a second LED (41, D2) configured to emit light in a bandwidth of 850 nm ±20 nm,
    a third LED (42, D3) configured to emit light in a bandwidth of 1550 nm ±20 nm and
    a fourth LED (45, D4) configured to emit light in a bandwidth of 405 nm ±20 nm,
    wherein each said arrangement of four LEDs (40, 41, 42, 45; D1, D2, D3, D4) is mounted on a single LED socket (38, 47) being soldered on said PCB (39) as SMD, and
    wherein said array is configured to irradiate patient's head for stimulating bio-chemical effects to ease patient's impairments due to Parkinson's disease.
  2. The device of claim 1, comprising an integrated ear/nose module (55) with two coherent laser-light sources configured to irradiate in a bandwidth of 850 nm ±1 nm, for simultaneous usage of head-irradiation, and ear- or nose-irradiation.
  3. Device of claim 1, configured to independently and sequentially control irradiation segments comprising five frontal segments (61), seven side and back segments (62), and a center-top segment (63).
  4. Device of claim 1, configured to adjust intensity in the range of 10 - 64 mW/cm2 , and to adjust duration in the range of 4 - 40 min.
  5. Device of claim 1,configured to provide incremental power increase at every irradiation cycle according to a stage generator signal.
  6. Device of claim 1, configured to provide selectable radiation patterns.
  7. Device of claim 1, configured to provide real time monitoring, controlling and data processing of essential electrical and environmental parameters.
  8. Device of claim 1, comprising up to 16 cascadable stations, simultaneously controllable, configured to acquire illumination data are for data analysis and diagnostic purpose.
  9. Device of claim 1, wherein said LED socket (38, 47) is a 5050 LED socket.
  10. Device of claim 1, configured to be remotely controlled.
  11. Device of claim 1, configured to provide irradiation adjustable overlay pulse frequency in the range of 10 Hz - 100 Hz.
EP20193781.0A 2020-09-01 2020-09-01 Irradiation therapy device for self-treating parkinson's disease Active EP3960234B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20193781.0A EP3960234B1 (en) 2020-09-01 2020-09-01 Irradiation therapy device for self-treating parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20193781.0A EP3960234B1 (en) 2020-09-01 2020-09-01 Irradiation therapy device for self-treating parkinson's disease

Publications (2)

Publication Number Publication Date
EP3960234A1 EP3960234A1 (en) 2022-03-02
EP3960234B1 true EP3960234B1 (en) 2024-10-30

Family

ID=72428135

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20193781.0A Active EP3960234B1 (en) 2020-09-01 2020-09-01 Irradiation therapy device for self-treating parkinson's disease

Country Status (1)

Country Link
EP (1) EP3960234B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023238956A1 (en) * 2022-06-10 2023-12-14

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100995427B1 (en) * 2008-06-13 2010-11-18 원테크놀로지 주식회사 Hair Growth Promoting Laser Therapy
US10112058B2 (en) * 2015-06-28 2018-10-30 Theradome, Inc. Smart laser hair growth helmet
US10780296B2 (en) * 2017-09-01 2020-09-22 Reni-Zoe Zivin Transcranial laser therapy for treatment of acute ischemic stroke
TWI702067B (en) * 2019-05-17 2020-08-21 百會科技有限公司 Portable phototherapy device

Also Published As

Publication number Publication date
EP3960234A1 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
TWI805710B (en) A system for performing non-invasive neurostimulation therapy of a living human brain of a subject
JP6714606B2 (en) Method, system and device for non-invasive neural stimulation of the brain
KR20250008743A (en) Photobiomodulation therapy garments, methods and uses
CN110801581A (en) Human brain light stimulation regulation and control device
US12390659B2 (en) Apparatus and method for photobiomodulation-based alternative to electrical vagus nerve stimulation and deep brain stimulation related to movement disorders
EP3960234A1 (en) Irradiation therapy device for self-treating parkinson's disease
CA2504857A1 (en) Portable rechargeable therapeutic device and method of using the same
EP3673954A1 (en) Device and method for inducing improvement of cerebral circulation
TWI903147B (en) Transcutaneous electrical nerve stimulation device with thermal modalities for stimulating acupoints of a patient with dementia
US20220409921A1 (en) Transcranial stimulator for rehabilitation based on photobiomodulation mechanism
WO2024097374A2 (en) Methods and devices for photobiomodulation
Kaffash et al. Photobiomodulation Therapy: Survey and Principal Study Leading to Design Rules for Implants
WO2024119165A2 (en) Methods and devices for photobiomodulation
US20250262454A1 (en) Methods and devices for photobiomodulation
CA3070333C (en) System and method for automated personalized brain modulation with photobiomodulation
WO2026060504A1 (en) Configuration applied to transcranial photobiomodulation equipment
Harauzov et al. Electrophysiological Response of the Non-Anesthetized Primate Brain to Minimally Invasive Local Infrared Neural Stimulation in Chronic Experiments
HK40111909A (en) Transcutaneous electrical nerve stimulation device with thermal modalities for stimulating acupoints of a patient with dementia
KR20130127074A (en) Easy adjustable optical stimulation system

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220711

RBV Designated contracting states (corrected)

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240321

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

INTG Intention to grant announced

Effective date: 20240702

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020040176

Country of ref document: DE

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250228

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1736350

Country of ref document: AT

Kind code of ref document: T

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250131

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020040176

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

26N No opposition filed

Effective date: 20250731

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602020040176

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: H13

Free format text: ST27 STATUS EVENT CODE: U-0-0-H10-H13 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20260504

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250901

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20250901

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20250930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20241030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20260401

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250930

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250901

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20250930